|World’s leading expert on NAD metabolism to speak at #UpgradeXP2019
LOS ANGELES, April 03, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today its Chief Scientific Advisor, Dr. Charles Brenner, the world’s foremost authority on NAD metabolism and discoverer of nicotinamide riboside as a vitamin, will speak at the Sixth Annual Biohacking Conference, a three-day immersive experience for the human performance industry. Hosted by Upgrade Labs, the conference runs Friday, April 5 through Sunday, April 7, 2019 at the Beverly Hilton Hotel in Los Angeles.
Dr. Brenner’s presentation, titled "Elevate Your Cellular Resiliency: Why We Must Keep Our Electrons Flowing with NAD,” is scheduled to begin at 11:40 a.m. on Friday. The breakout session will explain cellular metabolism and the role of NAD as a key coenzyme in electron transport, which plays a crucial role in energy production for the body. Dr. Brenner will also reveal how metabolic stressors can compromise one’s NAD pool and why optimal NAD levels are important to enjoy a more resilient life.
“Dr. Brenner's addition to the already stellar line-up of speakers at this year's conference is very exciting,” says Martin Tobias, CEO Upgrade Labs. “His expertise in the field of biochemistry and in particular, NAD metabolism, is second to none and we are thrilled he can share his insight and experience with our attendees.”
ChromaDex has been a respected pioneer in the health, wellness, and nutritional ingredient categories for nearly 20 years. In 2018, the Company launched the TRU NIAGEN® PRO line for health care practitioners, featuring the highest dose of nicotinamide riboside available in a single capsule, at 300mg. Additionally, the Company began selling a version of TRU NIAGEN® for professional sports teams which maintains NSF International’s Certified for Sport® Certification.
For additional information on the science supporting Tru Niagen visit www.truniagen.com.
For tickets or more information on the 2019 Upgrade Labs XP’s Biohacking Conference, please visit xp.upgradelabs.com.
About TRU NIAGEN®:
TRU NIAGEN® is a branded dietary supplement brought to market by key nicotinamide riboside innovator and patent holder, ChromaDex. NIAGEN® nicotinamide riboside (NR), also supplied by ChromaDex, is the sole active ingredient in TRU NIAGEN®. Multiple clinical trials demonstrate NIAGEN® is proven to boost NAD (nicotinamide adenine dinucleotide) levels, which decline with age. Only NIAGEN® has twice been successfully reviewed under FDA's new dietary ingredient (“NDI”) notification program, and has also been successfully notified to the FDA as generally recognized as safe (“GRAS”).
ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2018, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Media Contact:
Alex Worsham, Director of Strategic Partnerships
ChromaDex Investor Relations Contact:
Brianna Gerber, Senior Director of FP&A and Investor Relations